Cedars-Sinai Cancer
Los Angeles's largest non-profit hospital's cancer enterprise, known for bladder cancer biology, glioma immunotherapy and the Molecular Twin AI project.
Cedars-Sinai Cancer unites the Samuel Oschin Comprehensive Cancer Institute with Cedars-Sinai's regional network across Los Angeles. Director Dan Theodorescu's laboratory showed in 2023 that loss of the Y chromosome in bladder cancer drives immune evasion and sensitivity to checkpoint blockade; Keith Black's neurosurgery programme pioneered dendritic cell vaccines for glioma; and the Molecular Twin initiative combines multi-omics and AI to model individual patients, starting with pancreatic cancer. The centre has strong kidney, prostate, lung and women's cancer programmes and a phase 1 unit, and is pursuing NCI designation.
- Bladder cancer biology
- Neuro-oncology immunotherapy
- Molecular Twin (AI and multi-omics)
Pages like this
not linked directly; found by shared links- PersonPadmanee Sharma
Shares Renal cell carcinoma, Bladder & urothelial cancer, Immune checkpoint inhibitors.
- IdeaCure-focused prizes: pay for verified long-term cures, not for drugs
Shares Glioma & glioblastoma, Pancreatic ductal adenocarcinoma.
- IdeaA national late-effects registry linking treatment exposures to outcomes decades later
Shares Data silos, Immune checkpoint inhibitors.
- TargetCD73 / adenosine axis
Shares Renal cell carcinoma, Pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors.
- ProductAvelumab
Shares Renal cell carcinoma, Bladder & urothelial cancer, Immune checkpoint inhibitors.
- IdeaReprogramme suppressive macrophages instead of trying to delete them
Shares Glioma & glioblastoma, Pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors.
- PersonPrimo N. Lara Jr.
- IdeaA perpetual platform trial in every major cancer, funded as infrastructure
Shares Bladder & urothelial cancer, Glioma & glioblastoma, Pancreatic ductal adenocarcinoma.